Related Experiment Video
Updated: Feb 18, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
Published on: July 17, 2019
Hunting for the mutant without the MAP(K)
Leon Tejwani1,2,3, Janghoo Lim1,2,3,4
1Yale University, Interdepartmental Neuroscience Program, 295 Congress Avenue BCMM454C, New Haven, CT 06510, USA.
Researchers found two kinases, MAPK11 and HIPK3, increase toxic mutant huntingtin protein levels in Huntington's disease (HD). Targeting these kinases offers a new therapeutic strategy for HD treatment.
Area of Science:
- Molecular Biology
- Neuroscience
- Genetics
Background:
- Huntington's disease (HD) is a neurodegenerative disorder characterized by the accumulation of mutant huntingtin protein.
- Identifying key regulators of mutant huntingtin protein levels is crucial for developing effective HD therapies.
Purpose of the Study:
- To identify novel regulators of mutant huntingtin protein levels.
- To explore potential therapeutic targets for Huntington's disease.
Main Methods:
- Utilized molecular biology techniques to investigate kinase activity.
- Employed experimental model systems relevant to Huntington's disease.
Main Results:
- Identified MAPK11 and HIPK3 as positive regulators of mutant huntingtin protein levels.
- Validated these kinases as potential therapeutic targets through knockdown experiments.
Conclusions:
- MAPK11 and HIPK3 play a significant role in the pathology of Huntington's disease.
- Targeting MAPK11 and HIPK3 presents a promising therapeutic avenue for Huntington's disease treatment.
Related Concept Videos
MAPK Signaling Cascades
In-vitro Mutagenesis
Microtubule Associated Proteins (MAPs)
Abnormal Proliferation
Microtubule Instability
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...

